Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.59 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 14/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.36 |
| ▸ | CDK4 | P11802 | 10/20 | 0.36 |
| ▸ | CCND1 | P24385 | 10/20 | 0.36 |
| ▸ | CDK1 | P06493 | 10/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 9/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 0.36 |
| ▸ | CCND2 | P30279 | 5/20 | 0.36 |
| ▸ | CCND3 | P30281 | 5/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194745 | 0.75 | MYC (0.41) | CDK2MYCWDR5 | |
| SCHEMBL960172 | 0.75 | CDK2 (1.00) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL6691895 | 0.73 | CDK2 (0.68) | CDK2MYCWDR5CCNE2CCNE1 | |
| SCHEMBL5789785 | 0.73 | CDK2 (0.39) | CDK2MYCWDR5 | |
| SCHEMBL5213810 | 0.72 | CDK2 (0.67) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL14394720 | 0.72 | CDK2 (0.67) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL20583097 | 0.71 | CDK2 (0.48) | CDK2MYCWDR5CCNE2CCNE1 | |
| SCHEMBL20583155 | 0.70 | CDK2 (0.50) | CDK2MYCWDR5CCNE2CCNE1 | |
| SCHEMBL956877 | 0.69 | GRM4 (0.49) | CDK2MYCWDR5 | |
| SCHEMBL14076535 | 0.69 | CDK2 (0.62) | CDK2CCNE2CCNE1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303514-B9 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2006-11-08 | — | — | EP | claimed |
| EP-1303514-B1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | claimed |
| US-20040063767-A1 | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) | CHEN BANG-CHI (US) | 2004-04-01 | — | — | US | claimed |
| EP-1303514-A1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020099217-A1 | Process for preparing azacycloalkanoylaminothiazoles | CHEN BANG-CHI (US) | 2002-07-25 | — | — | US | claimed |
| US-6414156-B2 | EFFICENT, NOTOXIC PROCESS OF MAKING NEW KEY INTERMEDIATE QUATERNARY AMMONIUM SALTS AND 2-OXAZOLYLALKYL SULFIDE DERIVATIVES AND AVOIDS THE REACTION OF A-HALOKETONES WITH AN AZIDE FOLLOWED BY REDUCING THE RESULTING A-AMINOKETONE | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | claimed |
| WO-2002010163-A1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | claimed |
| US-20010006976-A1 | Process for preparing azacycloalkanoylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099217-A1 | Process for preparing azacycloalkanoylaminothiazoles | CDK9, CDK4, CDK6 | CDK2 15/4885MYC 104/4885WDR5 2618/4885 |
| US-20010006976-A1 | Process for preparing azacycloalkanoylaminothiazoles | CDK9, CDK4, CDK6 | CDK2 15/4885MYC 104/4885WDR5 2618/4885 |
| US-20040063767-A1 | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) | CDK9, CDK4, CCNI | CDK2 19/4885MYC 165/4885WDR5 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.